Insmed Inc (INSM)

[rstor1]

From the YMB, curtesy of Biowatchdog:

If this is true then revenues will start earlier than anticipated, and it also means that a reinbursable price point has been agreed to. For the hell of it, I checked with my provider - Oxford Health Care - and they don't have either on their list.

Can you folks that have other health plans check to see if either drug is available yet, and report here?


"Harvard Pilgrim HealthCare
by: biowatchdog 02/09/06 12:01 pm
Msg: 65448 of 65472

FDA approves new treatments for growth failure
January 2006

The Food and Drug Administration recently approved two recombinant insulin-like growth factor products, mecasermin recombinant (Increlex) and mecasermin rinfabate (Iplex) for the treatment of idiopathic short stature (ISS). Both drugs are specifically indicated for the treatment of growth failure in pediatric patients with primary insulin-like growth factor deficiency, or those with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.

Both products are expected to be available this month.(That seems to mean January) Both will require prior authorization by Harvard Pilgrim, and will be included in the Specialty Pharmacy Program.You’ll find more detailed information about criteria, as well as forms to match those criteria through our Medication Prior Authorization Program on our Web site upon product launch.

bwd "